BG Medicine Q3 Revenues Spike as Restructuring Aims to Ramp up Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that revenues in the third quarter rose 258 percent year over year on the sale of it BGM Galectin-3 test.

Separately, the Waltham, Mass.-based firm also announced a commercialization strategy intended to accelerate adoption of its cardiovascular diagnostics tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.